Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43693 | 0.98 | PRKCA (0.32) | PRKCA | |
| SCHEMBL27209491 | 0.97 | PRKCA (0.32) | PRKCA | |
| SCHEMBL3636262 | 0.97 | PRKCA (0.32) | PRKCA | |
| SCHEMBL4538371 | 0.97 | — | — | |
| SCHEMBL28455474 | 0.94 | — | — | |
| SCHEMBL2053511 | 0.93 | PRKCA (0.40) | PRKCA | |
| SCHEMBL9975942 | 0.93 | KMT2A (0.32) | — | |
| SCHEMBL1580301 | 0.93 | MEN1 (0.32) | — | |
| SCHEMBL13928656 | 0.93 | — | — | |
| SCHEMBL2725347 | 0.93 | MEN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736959-B2 | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-08-11 | — | — | US | disclosed |
| US-10668143-B2 | Meningococcus serogroup X conjugate | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-06-02 | — | — | US | disclosed |
| US-10188719-B2 | Conjugation of Streptococcal capsular saccharides | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2019-01-29 | — | — | US | disclosed |
| US-20180153983-A1 | CONJUGATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR POLYSACCHARIDES | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2018-06-07 | — | — | US | disclosed |
| US-9839686-B2 | Conjugation of Staphylococcus aureus type 8 capsular polysaccharides | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-12-12 | — | — | US | disclosed |
| US-20170246285-A1 | Conjugation of Streptococcal Capsular Saccharides | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2017-08-31 | — | — | US | disclosed |
| US-9675691-B2 | Conjugation of streptococcal capsular saccharides | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668143-B2 | Meningococcus serogroup X conjugate | O60361, MLEC, PDHX | PRKCA 4275/4885 |
| US-10188719-B2 | Conjugation of Streptococcal capsular saccharides | FUT5, CSGALNACT1, B3GNT2 | PRKCA 4172/4885 |
| US-20170246285-A1 | Conjugation of Streptococcal Capsular Saccharides | FUT5, CSGALNACT1, B3GNT2 | PRKCA 4172/4885 |
| US-20180153983-A1 | CONJUGATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR POLYSACCHARIDES | FUT8, FUT5, CSGALNACT1 | PRKCA 3592/4885 |
| US-10736959-B2 | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides | FUT8, FUT5, CSGALNACT1 | PRKCA 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.